Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.15)
# 1,193
Out of 5,090 analysts
161
Total ratings
47.1%
Success rate
0.42%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Downgrades: Neutral | n/a | $12.93 | - | 3 | Nov 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $7.59 | +242.56% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $44.26 | +42.34% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $7.02 | +1,994.02% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $68.48 | +19.74% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.49 | +33.51% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $26.42 | +5.98% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.06 | +843.40% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $38.55 | +169.78% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $3.32 | +562.65% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.09 | +569.86% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $121.22 | -23.28% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $44.90 | +51.45% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $23.63 | +348.58% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.98 | +150.84% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $20.28 | +176.13% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $9.61 | +493.13% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $3.74 | +488.24% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.42 | +602.48% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.32 | +954.22% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $66.62 | -42.96% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $71.63 | -0.88% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $3.33 | +50.15% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $44.41 | -14.43% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.13 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.12 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $13.07 | +1,965.80% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $181.30 | - | 2 | Apr 23, 2020 |
Astria Therapeutics
Nov 12, 2025
Downgrades: Neutral
Price Target: n/a
Current: $12.93
Upside: -
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $7.59
Upside: +242.56%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $44.26
Upside: +42.34%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $7.02
Upside: +1,994.02%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $68.48
Upside: +19.74%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.49
Upside: +33.51%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $26.42
Upside: +5.98%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.06
Upside: +843.40%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $38.55
Upside: +169.78%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $3.32
Upside: +562.65%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.09
Upside: +569.86%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $121.22
Upside: -23.28%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $44.90
Upside: +51.45%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $23.63
Upside: +348.58%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.98
Upside: +150.84%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $20.28
Upside: +176.13%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $9.61
Upside: +493.13%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $3.74
Upside: +488.24%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.42
Upside: +602.48%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.32
Upside: +954.22%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $66.62
Upside: -42.96%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $71.63
Upside: -0.88%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $3.33
Upside: +50.15%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $44.41
Upside: -14.43%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.13
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.12
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $13.07
Upside: +1,965.80%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $181.30
Upside: -